Deadline: 30-Oct-2025
The Breakthrough T1D has announced a new funding opportunity designed to support bold and transformative research aimed at accelerating progress toward its mission.
The Innovative Grant Mechanism provides seed funding for projects that tackle key unanswered questions in type 1 diabetes (T1D) research and hold the potential to challenge conventional wisdom or lead to groundbreaking discoveries.
Unlike traditional research grants, this program is specifically intended to fund highly innovative, high-risk-high-reward concepts that may change existing paradigms. Preliminary data is not required, but proposals must present a plausible and testable concept or hypothesis with a well-defined goal that can be achieved within the award’s timeframe and budget. Projects focused on incremental advancements, or those with the sole objective of generating new reagents or resources, are not eligible.
The grants provide one year of funding for up to USD 200,000, including indirect costs. The awards are non-renewable, and recipients are required to submit final progress and expenditure reports within 75 days of the project’s completion.
The program is open to applicants from both domestic and international non-profit or public organizations, including universities, medical institutions, hospitals, laboratories, and government agencies. Eligible applicants must hold a doctoral-level degree such as M.D., Ph.D., D.V.M., D.M.D., or D.O., and hold a faculty or equivalent position at a recognized institution. There are no citizenship restrictions, reflecting Breakthrough T1D’s commitment to fostering global collaboration.
To ensure excellence and diversity, the program encourages applications from women, individuals with disabilities, and members of underrepresented minority groups in science. By investing in bold ideas at their earliest stages, Breakthrough T1D aims to drive the discovery of novel pathways, approaches, and solutions that could significantly advance the fight against type 1 diabetes.
For more information, visit Breakthrough T1D.
